About Us
About Us
Revolutionizing Vascular Health Monitoring
At IDAHealth, we are committed to innovation in healthcare. Our flagship product, IdaFlo TR, represents a leap forward in transradial procedural care. This single-use, wireless wrist bracelet continuously monitors radial artery flow, providing real-time alerts to healthcare professionals. By enabling early detection of and preventing radial artery occlusion, IdaFlo TR safeguards patient wellbeing, ensures arterial health post-procedure, and sets new standards in arterial
compression management post-PCI.
Our Mission
We exist to make Patent Hemostasis effortless after every transradial (TR) procedure - enabling faster recovery, safer outcomes, and preserved radial access for life, while improving workflow efficiency and patient throughput for hospitals.
Our Vision
Our vision is to redefine post-procedural care by turning Patent Hemostasis into a data-driven, efficient standard that accelerates recovery, increases throughput, and reduces complications across health systems worldwide.
A Future Built on Innovation
With the incidence of radial artery occlusion (RAO) as a prevalent complication post- transradial intervention, IdaHealth's solutions are more crucial than ever. Our approach is rooted in extensive research and a deep understanding of the clinical landscape, addressing pervasive unmet needs within the medical community.
Board of Directors
David L. Camp, Jr
With 25+ years of experience in medical device innovation, specializing in corporate operations, business development, sales, and marketing. Served as CEO of Orbus Medical Technologies (acquired by
OrbusNeich). Holder of numerous international and US patents.
Danny de Vries
Expert in steering the development of cutting-edge medical devices and systems, with a proven track record in managing complex R&D initiatives.
Rob de Ree
Rob de Ree served as CEO of Dezima Pharma (acquired by Amgen) and BMEYE (acquired by Edwards Lifesciences). He previously held leadership roles at Crucell, Medtronic, and Byk Gulden. Currently, he is a board member at Sirius Medical and an operating partner at Biogeneration Ventures. Rob holds a PharmD from the University of Groningen.
Kees Kolff
After a successful management buy out of a global business solutions company, ADM Group, Kees managed operations across EMEA and Asia before returning to Europe to take on the role of Executive Director. In this capacity, he focused on business development and M&A. Currently, he serves as an ambassador for ADM Group and as Chairman of the Board for one of its subsidiaries, ADM 360, a specialized solutions company within the hospitality industry.
Scientific Advisory Board
Dr. G. Amoroso, MD, PhD
Medical Director, OLVG Hospital
Key Opinion Leader in transradial
coronary procedures and miniaturization of interventional devices.
Prof. Stephane Carlier
University of Mons (UMONS)
Chief of Cardiology and Interventional Cardiologist at University Hospital Helora (Mons, Belgium) and Professor at UMons. An expert in complex coronary interventions, and AI in atrial fibrillation prediction, he also founded Coeur CoreLab and serves on advisory boards and journal review panels.
Dr. Jim Nolan
Leeds, United Kingdom
Professor James Nolan is a KOL in the field of optimized vascular access practice, with a strong track record of research, education, and training in trans-radial procedures
Daily Operations
David L. Camp, Jr
CEO and Co-Founder
Dr. G. Amoroso, MD, PhD
Medical Director
Lucien van Os
CTO
Kees Kolff
CCO
Marcel Haan
COO
